Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.

about

Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.

Item

http://www.wikidata.org/entity/Q47103417

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Dose/Exposure-Response Modelin ...... nts with Rheumatoid Arthritis.

@en

Dose/Exposure-Response Modelin ...... nts with Rheumatoid Arthritis.

@nl

type

Item

label

Dose/Exposure-Response Modelin ...... nts with Rheumatoid Arthritis.

@en

Dose/Exposure-Response Modelin ...... nts with Rheumatoid Arthritis.

@nl

prefLabel

Dose/Exposure-Response Modelin ...... nts with Rheumatoid Arthritis.

@en

Dose/Exposure-Response Modelin ...... nts with Rheumatoid Arthritis.

@nl

P1476

Dose/Exposure-Response Modelin ...... nts with Rheumatoid Arthritis.

@en

P2093

Charles Ernest

http://www.w3.org/2001/XMLSchema#string

Lai San Tham

http://www.w3.org/2001/XMLSchema#string

Laiyi Chua

http://www.w3.org/2001/XMLSchema#string

Terence Rooney

http://www.w3.org/2001/XMLSchema#string

William Macias

http://www.w3.org/2001/XMLSchema#string

Xin Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Janus kinase inhibitors in autoimmune diseases

The molecular biology of erythropoietin

CPT: Pharmacometrics and Systems Pharmacology

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Clinical trial simulation in drug development.

JAKs and STATs in immunity, immunodeficiency, and cancer.

Model-based drug development: the road to quantitative pharmacology.

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts.

P304

804-813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PSP4.12251

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28891251

http://www.w3.org/2001/XMLSchema#string

P932

5744177

http://www.w3.org/2001/XMLSchema#string